From shortage to success: How MUSC anesthesia team navigated IV fluid crisis

As we approach the first anniversary of flooding from Hurricane Helene that devastated parts of North Carolina, the ...
Becker's ASC

Beating the IV fluid crisis: 1 system’s success

In September 2024, Hurricane Helene damaged a Baxter International plant in Marion, N.C., that produces 60% of the U.S.’s IV fluid products, disrupting ASCs and other healthcare facilities across the ...
Contract Pharma

Celltrion Launches Avtozma IV Formulation in the U.S.

Avtozma was FDA-approved in January 2025 to treat the same conditions as the reference product Actemra (tocilizumab).

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has ...
Pharmaceutical Technology on MSN

NMPA approves Eisai and Biogen for Leqembi IV maintenance dosing

China's National Medical Products Administration (NMPA) has granted approval for four-weekly intravenous (IV) maintenance ...
Clinical Trials Arena on MSN

Anebulo begins Phase I trial of IV cannabis antidote

Anebulo previously evaluated selonabant as an oral treatment in a Phase II clinical trial, demonstrating potential for ...